PROGRAM CO-CHAIRS
Marla Dubinsky, MD
Co-director Susan and Leonard Feinstein
IBD Clinical Center
Professor of Pediatrics and Medicine
Icahn School of Medicine Mount Sinai
Chief, Division of Pediatric GI and Nutrition
New York, NY
Parambir S. Dulai, MD
Associate Professor of Medicine
Director of GI Clinical Trials
Director of Precision Medicine
Division of Gastroenterology and Hepatology
Northwestern University Feinberg School of Medicine
Chicago, IL
PROGRAM OVERVIEW
This case-based enduring activity will focus on the epidemiology, pathophysiology, diagnosis, and treatment of ulcerative colitis (UC), and aims to result in clinical improvement in the management of UC through an increased understanding of how UC with bowel urgency affects quality of life and clinical outcomes in patients; and an increased ability to apply the latest clinical data on new and emerging agents, and their impact on bowel urgency, to treatment decision making.
TARGET AUDIENCE
This activity is designed to meet the identified educational needs of gastroenterologists, nurse practitioners, physician assistants, and other clinicians treating patients with ulcerative colitis.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Assess the safety, efficacy, and mechanisms of action of recently approved and emerging therapies for the treatment of patients with ulcerative colitis
- Explain the impact of bowel urgency on quality of life and clinical outcomes in patients with ulcerative colitis
- Apply optimal strategies to assess and manage bowel urgency in patients with ulcerative colitis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Faculty Member | Disclosures |
Marla Dubinsky, MD | Discloses that she has received consulting fees from Abbvie, Arena, Astra Zeneca, BMS, Boehringer Ingelheim, Eli Lilly, Gilead, Janssen, Pfizer, and Takeda. |
Parambir S. Dulai, MD | Discloses that he has received consulting fees from Takeda, Janssen, Abbvie, Pfizer, Abivax, BMS, GSK, Lilly, and Roivant Sciences; fees for participation on a speaker’s bureau from Janssen and Abbvie; and fees for contracted research from BMS |
All relevant financial relationships have been mitigated.
CME Content Review
‘The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Dave Chatman, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures
- Participate in the enduring activity
- Complete the online post-test and evaluation
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: May 30, 2023
EXPIRATION DATE: May 30, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.